Amylyx Pharmaceuticals Reports Positive Phase 3 LUCIDITY Trial Results and Q3 2026 Financials
Amylyx Pharmaceuticals (AMLX) announced positive top-line results from its Phase 3 LUCIDITY clinical trial for avexitide. The study met its primary endpoint, demonstrating a 55% reduction in the composite rate of level two and level three hypoglycemic events compared to a placebo, with high statistical significance (p-value of 0.000003). Following these results, the company remains on track to submit a New Drug Application by the end of 2026. Financially, Amylyx reported a net loss of $45.5 million for the third quarter of 2026, compared to $34.4 million in the prior-year period. Despite increased operating expenses driven by R&D and pre-commercialization activities, the company's liquidity position significantly improved. Cash and marketable securities rose to $768.1 million as of September 30, 2026, bolstered by a $544.6 million upsized public offering completed in August.
Tickers: $AMLX
Topics: cash runway clinical trials earnings report financial results